Q-omics provides the consensus-scored HTR3B profile across patient tissues and cancer cell-line models. HTR3B expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, HTR3B is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, HTR3B RNA expression shows 13,203 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where HTR3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HTR3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HTR3B survival associations across molecular data types. HTR3B RNA expression shows survival associations in the most cancer types (16), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HTR3B RNA expression–survival associations across cancer types. High HTR3B expression shows unfavorable associations in MESO and THYM, but favorable associations in UVM, CESC, ESCA and LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for HTR3B RNA expression.
This table summarizes HTR3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HTR3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HTR3B shows lower tumor expression in HNSC, KIRC, KIRP, COAD, STAD and READ. The HNSC box plot shows higher HTR3B RNA expression in normal versus tumor tissue (log2 FC = −0.936, t-test p < 0.001).
This table shows molecular features associated with HTR3B in patient tissues and cancer cell lines. In patient samples, HTR3B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HTR3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
